AstraZeneca stops prostate cancer trial, Q1 revenue up 10% to $13.6b
HQ Team April 29, 2025: British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal.
Drugs
Health
Pharma
Drugs
Pharma
Dabur India forecasts low to single-digit Q3 revenue growth
Dabur India, an ayurvedic and natural healthcare company, forecasts a low to mid-single-digit revenue growth for the third quarter ending December 31 due.